Segment Reporting - Schedule of Reconciliation of Segment Profits to Income before Taxes (Details) - USD ($) $ in Millions |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Segment Reporting [Line Items] | ||||
| Sales | $ 16,607 | $ 15,806 | $ 32,893 | $ 31,335 |
| Less segment costs: | ||||
| Cost of sales | 4,395 | 3,557 | 8,590 | 6,976 |
| Selling, general and administrative | 2,904 | 2,649 | 5,604 | 5,202 |
| Research and development | (9,741) | (4,048) | (22,333) | (7,669) |
| Other segment items | (99) | 7 | (237) | 43 |
| Pretax loss | (683) | 4,999 | (4,217) | 10,902 |
| Other profits | (683) | 4,999 | (4,217) | 10,902 |
| Unallocated: | ||||
| Interest income | 35 | 69 | 70 | 178 |
| Interest expense | (525) | (305) | (1,004) | (618) |
| Amortization | (1,915) | (1,198) | ||
| Depreciation | (1,180) | (1,020) | ||
| Research and development | (9,741) | (4,048) | (22,333) | (7,669) |
| Restructuring costs | (151) | (560) | (346) | (629) |
| Total segment profits | ||||
| Segment Reporting [Line Items] | ||||
| Sales | 16,535 | 15,696 | 32,675 | 30,922 |
| Less segment costs: | ||||
| Pretax loss | 12,248 | 11,696 | 24,510 | 23,199 |
| Other profits | 12,248 | 11,696 | 24,510 | 23,199 |
| Unallocated: | ||||
| Depreciation | (85) | (63) | (176) | (124) |
| Total segment profits | Pharma- ceutical | ||||
| Segment Reporting [Line Items] | ||||
| Sales | 14,760 | 14,050 | 29,109 | 27,688 |
| Less segment costs: | ||||
| Cost of sales | 1,731 | 1,601 | 3,284 | 3,174 |
| Selling, general and administrative | 1,437 | 1,367 | 2,750 | 2,611 |
| Research and development | 0 | 0 | 0 | 0 |
| Other segment items | (20) | (21) | (76) | (70) |
| Pretax loss | 11,612 | 11,103 | 23,151 | 21,973 |
| Other profits | 11,612 | 11,103 | 23,151 | 21,973 |
| Unallocated: | ||||
| Depreciation | (1) | (1) | (2) | (2) |
| Research and development | 0 | 0 | 0 | 0 |
| Total segment profits | Animal Health | ||||
| Segment Reporting [Line Items] | ||||
| Sales | 1,775 | 1,646 | 3,566 | 3,234 |
| Less segment costs: | ||||
| Cost of sales | 715 | 659 | 1,389 | 1,258 |
| Selling, general and administrative | 304 | 284 | 585 | 544 |
| Research and development | (120) | (110) | (232) | (205) |
| Other segment items | 0 | 0 | 1 | 1 |
| Pretax loss | 636 | 593 | 1,359 | 1,226 |
| Other profits | 636 | 593 | 1,359 | 1,226 |
| Unallocated: | ||||
| Depreciation | (84) | (62) | (174) | (122) |
| Research and development | (120) | (110) | (232) | (205) |
| Other profits | ||||
| Segment Reporting [Line Items] | ||||
| Sales | 72 | 110 | 218 | 413 |
| Less segment costs: | ||||
| Research and development | (9,577) | (3,844) | (21,981) | (7,321) |
| Pretax loss | 30 | 30 | 136 | 231 |
| Other profits | 30 | 30 | 136 | 231 |
| Unallocated: | ||||
| Interest income | 35 | 69 | 70 | 178 |
| Interest expense | (525) | (305) | (1,004) | (618) |
| Amortization | (984) | (601) | (1,915) | (1,198) |
| Depreciation | (513) | (455) | (1,004) | (896) |
| Research and development | (9,577) | (3,844) | (21,981) | (7,321) |
| Restructuring costs | (151) | (560) | (346) | (629) |
| Other unallocated, net | $ (1,246) | $ (1,031) | $ (2,683) | $ (2,044) |
| X | ||||||||||
- Definition Other net expenses not allocated to segments. No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|